Takeda Sets Eyes to Globally Market AMAG’s Anemia Drug
By PharmaDeals Analyst
Pharma Deals Review: Vol 2010 Issue 4 (Table of Contents)
Published: 23 Apr-2010
DOI: 10.3833/pdr.v2010.i4.1328 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Osaka based pharma giant Takeda Pharmaceuticals and AMAG Pharmaceutical announce an exclusive licensing deal, potentially worth USD 280 M, to market Feraheme® (ferumoxytol) globally, a therapeutic iron compound to treat iron deficiency anemia (IDA)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS